05 May, 2026
05 May, 2026
Epigenetic cancer therapy works differently from most cancer treatments. Rather than destroying cancer cells, it attempts to reprogram them by correcting the gene expression changes that caused them to behave abnormally in the first place.
Every cell in the body has a set of molecular switches that control which genes are active and which are not. In cancer, these switches malfunction. Epigenetic therapy targets those switches directly, working to restore normal gene function so that cancer cells either stop dividing or revert to healthier behavior, without the collateral damage that comes with chemotherapy or radiation.
Some epigenetic drugs are already in clinical use. DNA methyltransferase inhibitors and histone deacetylase inhibitors are currently approved for blood cancers, including myelodysplastic syndrome and certain lymphomas, and research into their role in solid tumors is ongoing.
| Feature | Genetic Approach | Epigenetic Approach |
|---|---|---|
| Target | DNA sequence mutations | Chemical tags on DNA/histones |
| Mechanism | Gene editing or replacement | Chromatin remodeling, methylation reversal |
| Reversibility | Permanent | Reversible |
| Side Effect Profile | Broad genomic disruption | More targeted, less collateral damage |
Epigenetic therapy does not rewrite your genes. It corrects the system that controls how genes are read.
In cancer, protective genes get chemically silenced, not because the DNA is broken, but because abnormal tags block them from working. These tags are placed by enzymes that the body uses to regulate which genes are active. In cancer, those enzymes lose their normal accuracy. Some become overactive, others get misdirected by mutations elsewhere in the cell, and the result is the same: chemical marks end up on genes that should never have been silenced. The genes most affected are typically the ones designed to control cell growth and flag abnormal cells for removal.
Epigenetic cancer therapy, or epigenetic therapy, removes those tags. Drugs like DNA methyltransferase inhibitors strip away abnormal methyl groups, while HDAC inhibitors loosen the protein structures that are keeping genes inaccessible. Both approaches work toward the same outcome, reactivating genes that cancer has switched off.
The DNA sequence itself is never cut, altered, or permanently changed.
Not exactly. In most cases, the problem is not an overactive cancer gene but a silenced protective one. Cancer frequently works by shutting down the genes responsible for keeping cell growth in check. Epigenetic therapy addresses this issue by reactivating those silenced genes rather than attacking the cancer cell directly.
DNA methylation inhibitors such as azacitidine and decitabine work through this mechanism. Both carry regulatory approval for myelodysplastic syndromes and certain leukemias, supported by published clinical trial data. In patients who respond, the effect is gradual; blood counts begin to normalize over successive treatment cycles as gene regulation is progressively restored.
There is no single moment of destruction. The cell is not killed. It is, in effect, reminded of how to regulate itself as to when to divide and when to stop.
Almost all types of epigenetic therapy work by targeting and correcting chemical changes that cancer cells make to silence or misread key genes that are involved in controlling cancer growth. The following are the different types of epigenetic therapy:
1. DNA Methylation Blockers
DNA methylation blocks gene expression by preventing cancer cells from adding chemical tags to genes that are supposed to remain active. Once those tags are cleared, the silenced protective genes can switch back on and resume their normal function. Azacitidine and decitabine are the two approved drugs in this class, used primarily in blood cancers such as myelodysplastic syndromes and acute myeloid leukemia.
2. HDAC Inhibitors
DNA wraps around proteins called histones, much like a thread wound around a spool. When that winding becomes too tight, genes cannot be read or activated. HDAC inhibitors work by loosening this winding, making important genes accessible again. Vorinostat, romidepsin, belinostat, and panobinostat are the four FDA-approved drugs in this class, used across several types of lymphoma and multiple myeloma.
3. EZH2 Inhibitors
EZH2 is a protein that stops genes responsible for suppressing tumor growth. In certain cancers, it becomes overactive and switches off genes that would otherwise keep tumor growth under control. Tazemetostat is the approved drug in this class, indicated for a type of soft tissue cancer called epithelioid sarcoma and for follicular lymphoma with EZH2 mutations.
4. IDH Inhibitors
In some leukemias, specific gene mutations occur in isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2), causing the abnormal production of an oncometabolite, namely, 2-hydroxyglutarate (2-HG), which blocks normal maturation. IDH inhibitors work by reducing 2-HG accumulation, allowing cells to function normally again. Ivosidenib and enasidenib are the two approved drugs in this class, both used in relapsed or refractory acute myeloid leukemia.
There is active research going on to understand how these drugs perform when they are administered in combination with other treatments, such as immunotherapy and chemotherapy for solid tumors, namely lung cancer, colorectal cancer, breast cancer, and ovarian cancer.
The table below gives an overview of the epigenetic therapy available for various types of cancer and its mechanisms of action against them:
| Cancer Type | Epigenetic Therapy Used | Type | Approval Status | How It Works |
|---|---|---|---|---|
| Myelodysplastic Syndromes (MDS) | Azacitidine, Decitabine | DNMT Inhibitor | FDA-approved | Inhibits DNA methyltransferase, reactivating silenced tumor suppressor genes |
| Acute Myeloid Leukemia (AML) | Azacitidine, Decitabine, Enasidenib, Ivosidenib | DNMT Inhibitor / IDH Inhibitor | FDA-approved | Reverses abnormal methylation; blocks mutant IDH enzymes |
| Cutaneous T-Cell Lymphoma | Vorinostat, Romidepsin | HDAC Inhibitor | FDA-approved | HDAC inhibitors restore normal gene regulation in malignant T-cells |
| Peripheral T-Cell Lymphoma | Romidepsin, Belinostat, Panobinostat | HDAC Inhibitor | FDA-approved | HDAC inhibition triggers cell cycle arrest and apoptosis in lymphoma cells |
| Multiple Myeloma | Panobinostat (with bortezomib) | HDAC Inhibitor | FDA-approved | HDAC inhibition combined with proteasome inhibition increases cancer cell death |
| Epithelioid Sarcoma | Tazemetostat | EZH2 Inhibitor | FDA-approved | Silences overactive EZH2, restoring normal gene activity |
| Follicular Lymphoma | Tazemetostat | EZH2 Inhibitor | FDA-approved | Blocks EZH2 mutations that silence genes controlling B-cell maturation |
| Non-Small Cell Lung Cancer | Azacitidine + immunotherapy | DNMT Inhibitor | Investigational | Under study to boost immunotherapy effectiveness |
No. Gene editing and epigenetic therapy are not the same.
Gene editing, such as CRISPR, works by physically cutting into the DNA sequence by removing, inserting, or rearranging specific segments of genetic code. These changes are permanent.
Epigenetic therapy never changes the DNA sequence. Instead, it changes chemical attachments and protein structures wrapped around it that are involved in deciding which genes a cell reads and which it ignores. These targeted chemical changes can reactivate the silenced gene and aid in controlling cancer growth. These changes are not permanent and can be adjusted based on the treatment response shown by the patient.
Patients on DNA methylation inhibitors or HDAC inhibitor regimens need consistent hematological monitoring throughout treatment. Fatigue and myelosuppression are the most common experiences, and neither should be managed passively.
Aftercare includes follow-up imaging, bone marrow assessments, and nutritional guidance. At comprehensive cancer hospitals, on-course teams and psycho-oncology services are built into the care pathway from day one. Rehabilitation is tailored to each patient's pace and tolerance, not a standardized schedule.
Supportive care quality across multiple cycles shapes outcomes as much as the drug itself.
Azacitidine-based regimens range from Rs. 40,000 to Rs. 120,000 per cycle, depending on facility and protocol. HDAC inhibitor regimens vary by drug availability and cycle frequency. Metro cities like Bangalore, Mumbai, and Kolkata typically carry higher facility charges than Tier 2 centers.
Costs vary by hospital and patient profile. Request a written estimate covering projected cycles, monitoring visits, and supportive medications before committing to any protocol.
Epigenetic therapy is an actively evolving area of precision oncology, and awareness is the first step toward making informed treatment decisions. Not all patients can undergo epigenetic therapy, and the tumor’s molecular profile, disease stage, and previous treatment strategy must be carefully assessed. Specialists at HCG Cancer Hospital encourage patients to have detailed conversations with their care team to explore epigenetic therapy as a treatment option.
During the discussion, asking the following questions may help patients make informed health decisions.
Disclaimer: This information is intended to educate patients and caregivers. It does not replace professional medical advice. All treatment decisions should be made in consultation with a qualified doctor.
Feel free to reach out to us.
